These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26506914)

  • 1. Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).
    Kim KH; Hong SJ; Han KS
    BMC Cancer; 2015 Oct; 15():812. PubMed ID: 26506914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y; Kim YS; Hong B; Cho YM; Lee JL
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
    Bamias A; Dafni U; Karadimou A; Timotheadou E; Aravantinos G; Psyrri A; Xanthakis I; Tsiatas M; Koutoulidis V; Constantinidis C; Hatzimouratidis C; Samantas E; Visvikis A; Chrisophos M; Stravodimos K; Deliveliotis C; Eleftheraki A; Pectasides D; Fountzilas G; Dimopoulos MA
    Ann Oncol; 2013 Apr; 24(4):1011-7. PubMed ID: 23136231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).
    Matsui Y; Ogawa O; Ishitsuka R; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Fujie K; Keino N; Nishiyama H
    Int J Clin Oncol; 2016 Dec; 21(6):1142-1149. PubMed ID: 27349431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
    Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
    Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
    Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.
    Edeline J; Loriot Y; Culine S; Massard C; Albiges L; Blesius A; Escudier B; Fizazi K
    Eur J Cancer; 2012 May; 48(8):1141-6. PubMed ID: 22364733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
    Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
    Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
    von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.